Funding profile · Clinical decision support
AgileMD
Fifteen years old, FDA cleared, and nearly invisible in the capital markets. Most of the money traceable to AgileMD through a government record is non-dilutive, and the SEC holds no Form D from the company at all.
$2.75MFederal dollars on record: an NIH R44 plus a BARDA DRIVe contract
$2.5MPrivate capital reported by Wellfound, one round, dated June 2012
0Form D filings in SEC EDGAR under any AgileMD entity
$5.0MEstimated 2024 revenue, third party estimate, 18 employees
Data as of September 22, 2026. Company-reported figures are labeled.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| 2011 | Prizes and university grants | Not disclosed | Kaplan New Venture Challenge, Chicago Biotech Consortium, UChicago Innovation Fund | Company-stated |
| Summer 2011 | Y Combinator batch note | $150,000 convertible, offered batch wide | Y Combinator, SV Angel, Start Fund | TechCrunch |
| 2012 | Rock Health, second batch | Not disclosed | Rock Health | TechCrunch |
| Jun 2012 | Seed | $2.5M in one round (Wellfound); $2.0M over four (Tracxn) | Not named by either | Aggregator |
| May 2021 | BARDA DRIVe contract 75A50121C00043 | $750,000 | BARDA | Public record |
| Sep 2021 | NIH SBIR Phase II, 1R44EB030955-01A1 | $1,995,966 | NIBIB | Public record |
| To Sep 2026 | Regulation D offering | None on file | None | Not found |
What the public records show
SEC EDGAR · Form D search · run Sep 22, 2026
- Company index
- No matching companies for AgileMD
- Full text
- Zero Form D hits for the term AgileMD
- Vehicles
- No SPV or fund filing naming the company
NIH · award 1R44EB030955-01A1 · FY2021
- Amount
- $1,995,966
- Mechanism
- R44 SBIR Phase II, to AGILEMD, INC.
- Institute
- NIBIB
- Investigator
- Dana Peres Edelson, co-founder and chief medical officer
- Period
- Sep 22, 2021 to Mar 21, 2025
BARDA DRIVe · contract 75A50121C00043 · May 5, 2021
- Amount
- $750,000, cost-share
- Purpose
- Finish regulatory work, pilot eCART in ten hospitals
- Downstream
- BARDA is a named collaborator on trial NCT05893420
Reading the filings
- The only capital a government record confirms is non-dilutive.$1,995,966 from NIH plus $750,000 from BARDA is $2,745,966, which matches the company’s repeated claim of nearly $3 million and is the only funding figure here checkable against a primary source.
- Grants outweigh reported equity.Against the $2.5 million Wellfound reports, federal money is about 52% of the roughly $5.25 million identifiable from any source. For a fifteen year old company with a cleared device, that is a very small dilutive stack.
- No Form D is a fact about filings, not about money.A company raising under Section 4(a)(2) files nothing. The absence rules out the usual trail, a priced round, an SPV, board seats on a cover page, but it does not prove no equity was sold.
- The aggregators disagree.Wellfound reports $2.5 million in one round dated June 14, 2012. Tracxn reports $2.0 million over four rounds, dates a seed to June 4, 2012, counts the 2021 NIH award as a round, and names a co-founder, Kurt Ericson, absent from the company’s own account and from contemporaneous reporting. GetLatka lists funding as $0. Treat all three as soft.
- The last dated private round is fourteen years old.If that is right, the 2019 Quant HC merger, the 2023 FDA submission and the commercial build since were paid for by revenue and federal awards. GetLatka estimates 2024 revenue at $5 million on 18 employees, about $278,000 per head. The NIH award ended March 21, 2025 with no successor on record, and the pivotal trial runs to December 2026.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Regulatory | FDA 510(k) K233253, cleared Jun 21, 2024, adults on medical-surgical wards. Pediatrics not covered. | Public record |
| Named customers | Yale New Haven Health (seven hospitals, live Jan 2024), UNC Health (Feb 2024), John Muir Health, BayCare, University of Wisconsin Health, UChicago Medicine. | Independent and partner |
| Outcome claim | Yale reports a 13% relative and 1.2% absolute mortality reduction since go live. Told to a trade outlet, not published. | Independent |
| Scale | Four company channels, four answers: 40,000 providers and 130 hospitals (2021), 135,000 and 250 (2024), 150,000 and 400 plus (website), 65,000 and 81 (Y Combinator profile). | Company figures disagree |
| Headcount | 19 (Y Combinator), 20 in Jul 2026 (Tracxn), 18 (GetLatka). | Company and aggregator |
What to watch
- A first Form D, due within 15 days of a first sale. It would be the company’s first, which makes it a signal rather than routine.
- A successor federal award to replace R44EB030955.
- Results from NCT05893420, primary completion estimated December 31, 2026.
- A pediatric clearance, which would widen the population beyond the adult label.
The AgileMD story on Healthcare DiscoveryHealthcare Discovery
Related companies
Sources
- Public recordSEC EDGAR company and Form D searches, no results
- Public recordNIH RePORTER award 1R44EB030955-01A1
- Public recordBARDA and AgileMD partnership announcement
- Public recordFDA 510(k) K233253
- Public recordClinicalTrials.gov NCT05893420 and NCT06771830
- IndependentAgileMD funding rounds and investors
- IndependentAgileMD company profile, funding and team
- IndependentAgileMD revenue and team size estimate
- IndependentYC, Rock Health-Backed Agile Diagnosis Launches
- IndependentHow Yale New Haven Health uses eCART
- CompanyAgileMD FDA clearance release, with federal funding disclosure
- CompanyAgileMD website and Y Combinator profile
Compiled from SEC, NIH, BARDA and FDA public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; the absence of one does not establish that no securities were sold. Healthcare Venture Capital Fund holds no position in AgileMD. This page is not an offer to sell or a recommendation to buy any security.